Hans Lennart Rudolf Wigzell
Known title: DirectorCIK: 0001492766
Associated companies
Transaction History
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | — | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 10,500 | $144K | 12/12/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 10,500 | $1.3M | 12/12/2024 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 15,000 | $209K | 3/8/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 11,745 | $1.4M | 3/8/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 100 | $12K | 3/8/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 3,155 | $391K | 3/8/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 1,846 | $0 | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 15,000 | $435K | 8/4/2023 | View on chart |
| SRPT | ▼ Sell | Open Market | 15,000 | $1.6M | 8/4/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 1,523 | $0 | 3/6/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 2,953 | $0 | 3/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.